Pituitary desensitization to gonadotropin-releasing hormone increases abdominal adiposity in hyperandrogenic anovulatory women  Daniel A Dumesic, M.D., David H Abbott, Ph.D., Joel R Eisner, B.S., Rebekah R Herrmann, Judd E Reed, Timothy J Welch, M.D., Michael D Jensen, M.D.  Fertility and Sterility  Volume 70, Issue 1, Pages 94-101 (July 1998) DOI: 10.1016/S0015-0282(98)00098-3

Figure 1 Regional body fat in hyperandrogenic patients and healthy women before and after 3 months of GnRH-a therapy. Values are antilog of the transformed mean and 95% CI. ∗ P≤0.05 versus all the women before GnRH-a therapy; † P≤0.05; ‡ P≤0.025 versus the same women before GnRH-a therapy; by ANOVA. The solid bar represents the hyperandrogenic patients; the open bar represents the healthy women. Fertility and Sterility 1998 70, 94-101DOI: (10.1016/S0015-0282(98)00098-3)

Figure 2 Changes in [1] visceral adipose area at the L2-3 vertebral interspace and [2] total visceral adipose volume in hyperandrogenic patients and healthy women after 3 months of GnRH-a treatment. Values are antilog of the transformed mean and 95% CI. The visceral adipose area and total visceral adipose volume increased significantly with GnRH-a treatment in the hyperandrogenic patients compared with the healthy women (paired t-test). The solid bar represents the hyperandrogenic patients; the open bar represents the healthy women. Fertility and Sterility 1998 70, 94-101DOI: (10.1016/S0015-0282(98)00098-3)

Figure 3 Visceral adipose area at the L2-3 vertebral interspace in a single healthy woman (BMI, 34.9 kg/m2) and a matched hyperandrogenic patient (BMI, 31.8 kg/m2) before and after 3 months of GnRH-a treatment. The visceral adipose area decreased by 9% (from 167.7 to 152.2 cm2) with GnRH-a treatment in the healthy woman but increased by 52% (from 72.4 to 110.3 cm2) in the hyperandrogenic patient. Fertility and Sterility 1998 70, 94-101DOI: (10.1016/S0015-0282(98)00098-3)